Efficacy of Vitamin E in Methotrexate-Induced Hepatotoxicity in Rheumatoid Arthritis: An Open-Label Case-Control Study
Table 1
Sociodemographic and clinical profiles of the study participants at baseline ().
Parameters
EVA group () (%) or
Non-EVA group () (%) or
value
Age (years)
0.332
Gender
Male
11 (10.4)
20 (16.1)
Female
95 (89.6)
104 (83.9)
BMI (kg/m2)
0.291
Occupation
Housewife
79 (74.5)
85 (68.5)
Service holder
8 (7.5)
14 (11.3)
Others
19 (18.0)
25 (20.2)
Education
Illiterate
23 (21.7)
17 (13.7)
Can sign only
21 (19.8)
27 (21.8)
Primary
6 (5.7)
10 (8.1)
Secondary
28 (26.4)
39 (31.4)
Higher secondary and above
28 (26.4)
31 (25.0)
Disease duration in months
0.197
MTX dose (mg per week)
(median, 15; mode, 20)
(median, 15; mode, 20)
0.215
Enthesitis#
43 (40.6)
55 (44.4)
Red eye
21 (19.8)
21 (16.9)
Rheumatoid nodules
1 (0.9)
1 (0.8)
Rheumatoid factor (IU/mL)
78 (76.5)
96 (77.4)
ACPA (U/mL)
72 (67.9)
90 (72.6)
CRP (mg/L) (median)
0.206
DAS 28
0.155
CDAI
0.329
BMI: body mass index; kg/m2: kilogram per square meter; ACPA: anticitrullinated protein antibodies; CRP: C-reactive protein; DAS 28: disease activity score for RA; CDAI: clinical disease activity index. Independent -test; #enthesitis included history of enthesitis in the past or present and subclinical enthesitis or tenosynovitis detected on musculoskeletal ultrasonography.
